key: cord-0901993-6mg51jp4 authors: Cañete, Roberto; Afonso, José A.; Brito, Katia title: Open Label, Evaluation of the effects of the uncontrolled use of Biomodulina T on the severity of SARS-CoV-2 infections in older Cuban Adults date: 2022-01-12 journal: Curr Ther Res Clin Exp DOI: 10.1016/j.curtheres.2022.100662 sha: ac50eaf410eef99ec8620869a6c9e7bc6fbb2603 doc_id: 901993 cord_uid: 6mg51jp4 Background The ongoing Covid-19 pandemic is a worldwide public health threat. Millions of people are at risk and older adults are more susceptible to developing the most serious manifestations of the disease, in part because the ageing of the immune system. Biomodulina T® is an injectable immune modulator that has been licensed for use in Cuba for many years. An open-label, uncontrolled trial was conducted to investigate whether it might be useful to prevent or modulate the serious effects of SARS-CoV-2 infections in older Cuban adults prior to the availability of vaccinations. Methods From April 12 to August 31, 2021, 1239 adults, sixty years and older, unvaccinated against COVID-19 were recruited from the José Luis Dubrocq polyclinics, to receive Biomodulina T®, one intramuscular 3 ml dose weekly for 6 weeks. Each person was visited at home weekly to be given Biomodulina T®. Once daily subjects were seen by a medical student to collect information on any possible adverse events related to the medication as well as any symptoms of COVID-19. The possible usefulness of the intervention and its potential adverse events were assessed based on the number of older adults who became infected with COVID-19, and the severity of any symptoms reported or noted both during the 6-week treatment period and during an additional 6 week post-treatment observation period. Results Sixteen subjects were diagnosed with symptomatic COVID-19 during the intervention using a specific RT-PCR. One subject died because of COVID-19. The most common pre-existing diagnoses in treated subjects included High Blood Pressure in 64.8%, Diabetes Mellitus in 19.85%, and Ischemic Cardiopathy in 13.88%. Biomodulina T® was well tolerated. Only infrequent, mild, transient, and self-limited adverse events were identified. Both the incidence of COVID-19 infections and the overall mortality rate were lower in the treated subjects than what was observed in the untreated general population of this Cuban province during the same time period. Conclusion While further, confirmatory, double-blind, controlled clinical trials are needed, Biomodulina T® injections were well tolerated, and the results of this open, uncontrolled study suggest that it may have been useful to decrease the incidence and severity of symptomatic SARS-CoV-2 infections in these older Cuban adults. The ongoing Covid-19 pandemic is a worldwide public health problem; with millions of people at risk of serious symptoms or death. 1 In an attempt to control or decrease further transmission, Cuba developed multiple strategies, in which the biotech industry has been deeply involved. 2, 3 As part of these strategies, twenty-three drugs are in use throughout the 3 country and five vaccine candidates are the subject of ongoing research. Three of these vaccines, -Abdala, Soberana 02, and Soberana Plus-, have now been approved by national authorities for emergency use but were not available when this study was initiated. The proportion of the adult population that is >60 years of age has steadily increased in Cuba as well as worldwide, and data suggest this increase will continue for many years to come. Because older adults are more likely to suffer the most serious manifestations of COVID-19, at least in part the result of the ageing of the immune system, it is especially important to identify methods to either prevent infections or mediate their effects in this population subgroup. While immunizations have now been proven to be effective in this and younger populations, there were no approved immunizations available in Cuba when the public health intervention described herein was designed and initiated. One of several Cuban products that was and still is in use for COVID-19 is Biomodulina T  , a biological immunomodulator of natural origin present in polypeptide fractions obtained from the bovine thymus. 4, 5 This medication exhibits cellular regeneration and immunomodulatory properties, presumably because it stimulates lymphoblastoid mitosis and thus the differentiation of T lymphocytes. In models of acute inflammation, edema and chronic inflammation, Biomodulina T  has been reported to illicit an anti-inflammatory response associated with the modulation of the induced inflammatory response, and inhibition of the release of arachidonic acid by macrophages. 6, 7 In a (2000) Cuban study, the authors reported that Biomodulina T  permitted the recovery of the thymic mass in children with atrophy or hypoplasia of the gland, with a subsequent increase in the release of hormones by thymic epithelial cells, as well as a decrease in recurrent infections. 8 Another clinical study suggested possible beneficial effects of this medication in patients with relapsing-remitting multiple sclerosis. 9 Biomodulina T  administration temporarily expands naïve CD4+ T-cell production, thymic emigrant cell production, and stem cell-like memory CD 8+ T-cell production. 10 Peripheral production and maintenance of the naïve T-cell repertoire is critical to normal immune system function. 5, 10 The biological effects of Biomodulina T  and the results of its clinical use suggest that it might be useful to reverse T-cell immunosenescence and restore the immune Older, unvaccinated adults (>60 years of age) were recruited to be given Biomodulina T  , one 3mL intramuscular dose once weekly for six weeks followed by an additional six week surveillance period. The total intervention lasted 12 weeks. Patients were excluded from the intervention for any of the following: (1) a history of sensitivity to Biomodulina T or, (2) having received any antibiotic, antiparasitic or steroid therapy in the preceding 4 weeks or, (3) from the presence of any chronic noncontrolled diseases or, (4) participation in another intervention or clinical trial, or (5) if they were judged by the study staff to be unlikely to attend all required follow-up visits. Eligible patients who had none of the exclusion criteria, and from whom written informed consent was obtained were enrolled in the intervention. The general and oral health of each subject were both evaluated during the first visit by both a generalist physician and a general odontologist respectively. The study team visited each subject once weekly at home to administer Biomodulina T  and to provide information about how to prevent COVID-19. In addition, a medical student visited each subject daily for the entire study period (6 weeks (Table 2) . Other, less commonly identified pre-existing diagnoses are also noted in Table 2 . Only 16 (1.3%) subjects developed laboratory confirmed symptomatic COVID-19 during the 12 week study period; 12 during the initial 6 weeks while receiving the shots, another three during the first month after completing the injections, and another, single patient who died from a severe COVID-19 infection 50 days after the final dose. All confirmed infected adults were symptomatic and their infections were diagnosed by RT-PCR. The incidence of COVID-19 observed among the people receiving the medication was equivalent to 1.291 per 100.000 individuals. This is less than the incidence reported in the Matanzas province during the same time period, (9.441 per 100.000 individuals). Similarly, the mortality rate (0.08%) was lower among individuals receiving the intervention than was reported for the general population of the province (0.81%) during this time period. The incidence and mortality data were collected from the daily and weekly reports for the Matanzas Office of the Cuban Biomodulina T  was well tolerated. Only mild, transient, and self-limited adverse events were notified. One hundred (8.07%) of the adult subjects reported pain at the injection site, five (0.4%) reported a headache, and ten (0.8%) weakness. No unexpected, or serious adverse events occurred, and none of the subjects needed to discontinue treatment or receive additional drugs to treat an adverse event. The current COVID-19 pandemic is a major public health problem affecting people of all ages. 5 despite the existence of national interventional strategies lead by the Cuban Ministry of Public Health, with the support and participation of the Cuban government, 2,3 in provinces throughout Cuba designed to preserve population safety and to reduce the number of hospitalization and deaths. It is well known that vaccination, wearing face masks, cleaning hands frequently, and keeping a safe distance from others are effective ways to decrease the number of SARS-CoV-2 new infections. However, infections still occur and due to the ageing of the immune system, people older than 60 years are more likely than younger people to suffer from the most serious consequence of these COVID-19 infections. These facts led the Public Health System in Matanzas, to begin this open label, uncontrolled health intervention: administration of Biomodulina T  to adults, sixty years and older, living in the capital city of the province. The intervention was given to 1239 nonvaccinated older adults and was begun at the same time that the most cases of COVID-19 were being identified in the territory. 8 The only vaccines available in Cuba during the time period of this study were those that were developed in Cuba. Vaccinations using these vaccines began in cluster groups such as public health workers and other first responders in the middle of the post-injection follow-up period of this study. In the municipality were the study population lived, vaccinations began in these clusters by July 2021, but were not available to the older adults included in this study until the second half of August, 2021 when only some of these subjects were in their surveillance phase. Vaccination was delayed in these subjects to allow them to finish the 15 days remaining in their participation. This delay was approved by the local IRB. Biomodulina T  is a biological immunomodulator of natural, biologic origin, composed of a specific extract from bovine thymus. The product has been in use in Cuba for more than 15 years with excellent results reported in reducing the frequency of upper respiratory infections, decreasing hospital admissions, and drug intake. 5, 8, 9, 11 Only sixteen treated older adults developed symptomatic COVID-19 during the intervention and only one of whom died, suggesting that non-vaccine technologies currently in use to prevent the transmission -face masks, cleaning hands frequently, and keeping a safe distance from others-when complemented by Biomodulina T  can be very effective in reducing the incidence of COVID-19. The open label, uncontrolled design limits the conclusions that can be drawn. In part this is because the injections were not the only intervention provided. The relationship created between the researchers and these older adults during the visits is likely to have influenced the outcomes. The researchers created an environment where information related to the pandemic and other health topics were shared and discussed and adapted to be more understandable to older adults. This relationship is likely to have improved the understanding and perception of these adults about the importance of using masks, cleaning hands frequently, and maintaining physical distancing. The incidence of COVID-19 among the elderly Cuban population receiving the medication was 1.291 per 100,000 individuals, which is less than the incidence at Matanzas in the same period of time of 9.441 per 100.000 individuals. The mortality rate was also much lower in the subjects given the intervention (0.08%) than that reported throughout the province (0.81%) despite being in a non-elderly population that did not receive these injections. Biomodulina T  was also well tolerated. Only relatively uncommon pain at the injection site, weakness, and headache were reported. While Biomodulina T  is not an anti COVID-19 medication, its immunomodulant effects may improve the immunological status of older adults and therefore allow them to better tolerate viruses like SARS-CoV-2. Double-blind, controlled clinical trials are needed to assess whether this biological product, when used in addition to vaccines and proven personal protective tools and social practices, can provide a way to reduce new symptomatic COVID-19 infections, hospitalization, or deaths in the elderly. Such studies might even be ethically possible in vaccine aversive populations. Vaccines have dramatically reduced the opportunity of humans to suffer the consequence of some infectious diseases including smallpox, poliomyelitis, tuberculosisis and yellow fever, however, in older adults, where T-cell immunosenescence naturally occurs, Biomodulina T ® could act as a vaccine enhancer. 4 Biomodulina T ® could be also useful in people with medical conditions where vaccination is ineffective, not recommended, or refused on religious or other grounds. While further, confirmatory, controlled clinical trials are needed, Biomodulina T ® injections were well tolerated was safe and the results of this open, uncontrolled study suggests that it may have been useful to prevent decrease the incidence and severity of SARS-CoV-2 infections in older Cuban adults in Matanzas. Table 1 Demographic characteristics of patients at admission as reported on data collection forms. Biomodulina treated group Values are presented as n (%). Coronavirus Disease-2019 (COVID-19): An Updated Review Gestión gubernamental y ciencia cubana en el enfrentamiento a la COVID-19 Protocolo de actuación nacional para la COVID-19 Havana: Ministry of Public Health (CU) Biomodulina T (InmunyVital®) Restores T Cells and Helps Contain COVID-19. Front Immunol Restore Immunity in Older Adults Havana: CECMED; c2019. Registros. Resumen de las características del producto Biomodulina T Estudio fase II de tratamiento de pacientes con esclerosis múltiple exacerbante remitente con Biomodulina T Efecto de la biomodulina t 1000 sobre el timo de niños con infecciones recurrentes Efecto de la Biomodulina T sobre las infecciones respiratorias altas y la polifarmacia del anciano T cell sub-populations in healthy elderly and lung cancer patients: insights from Cuban studies La industria biofarmacéutica cubana en el combate contra la pandemia de COVID-19 Assessment of hypertension management and control: a registrybased observational study in two municipalities in Cuba Offline: COVID-19 is not a pandemic Cuba's cardiovascular risk factors: International comparison of levels and education gradients Burden of hypertension and associated risks for cardiovascular mortality in Cuba: a prospective cohort study ISSN: versión electrónica 1561-4433